CA2376215A1 - The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder - Google Patents
The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder Download PDFInfo
- Publication number
- CA2376215A1 CA2376215A1 CA002376215A CA2376215A CA2376215A1 CA 2376215 A1 CA2376215 A1 CA 2376215A1 CA 002376215 A CA002376215 A CA 002376215A CA 2376215 A CA2376215 A CA 2376215A CA 2376215 A1 CA2376215 A1 CA 2376215A1
- Authority
- CA
- Canada
- Prior art keywords
- mph
- dose
- saline
- treatment
- study
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960001042 dexmethylphenidate Drugs 0.000 title claims abstract description 5
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 title claims abstract description 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title abstract description 10
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title abstract description 9
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 title abstract description 9
- 230000001225 therapeutic effect Effects 0.000 title description 3
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960001344 methylphenidate Drugs 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000013403 hyperactivity Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 239000011780 sodium chloride Substances 0.000 description 28
- 238000012360 testing method Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 230000006742 locomotor activity Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 11
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229960002319 barbital Drugs 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000027119 gastric acid secretion Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004031 partial agonist Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000010411 postconditioning Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 208000006550 Mydriasis Diseases 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 206010042008 Stereotypy Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 229960000632 dexamfetamine Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 229960005152 pentetrazol Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940099204 ritalin Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010067948 Compulsive shopping Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028714 Narcolepsy and hypersomnia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229950004681 zacopride Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9913458.7A GB9913458D0 (en) | 1999-06-09 | 1999-06-09 | The therapeutic use of d-threo-methylphenidate |
| GB9913458.7 | 1999-06-09 | ||
| PCT/GB2000/002234 WO2000074680A1 (en) | 1999-06-09 | 2000-06-08 | The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2376215A1 true CA2376215A1 (en) | 2000-12-14 |
Family
ID=10855048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002376215A Abandoned CA2376215A1 (en) | 1999-06-09 | 2000-06-08 | The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1185268B1 (enExample) |
| JP (1) | JP2003501387A (enExample) |
| AT (1) | ATE302006T1 (enExample) |
| AU (1) | AU766748B2 (enExample) |
| CA (1) | CA2376215A1 (enExample) |
| DE (1) | DE60022033T2 (enExample) |
| ES (1) | ES2243273T3 (enExample) |
| GB (1) | GB9913458D0 (enExample) |
| WO (1) | WO2000074680A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115631B2 (en) | 1995-12-04 | 2006-10-03 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| US7431944B2 (en) | 1995-12-04 | 2008-10-07 | Celgene Corporation | Delivery of multiple doses of medications |
| US7459560B2 (en) | 1997-05-22 | 2008-12-02 | Celgene Corporation | Processes and intermediates for resolving piperidyl acetamide stereoisomers |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101318806B1 (ko) | 2005-01-20 | 2013-10-16 | 인스티튜트 포 몰리큘러 메디신, 인코포레이티드 | 메틸페니데이트 유도체 및 그 용도 |
| WO2009146320A1 (en) | 2008-05-27 | 2009-12-03 | Dmi Life Sciences, Inc. | Therapeutic methods and compounds |
| CN108348775B (zh) | 2015-09-15 | 2021-07-02 | 普瑞西斯生物学研究有限责任公司 | 芬坎法明的前药 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9514451D0 (en) * | 1995-07-14 | 1995-09-13 | Chiroscience Ltd | Sustained-release formulation |
| US5908850A (en) * | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
| US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
| MX9805870A (enExample) * | 1996-01-22 | 1999-01-31 | ||
| US6210705B1 (en) * | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| US6025502A (en) * | 1999-03-19 | 2000-02-15 | The Trustees Of The University Of Pennsylvania | Enantopselective synthesis of methyl phenidate |
-
1999
- 1999-06-09 GB GBGB9913458.7A patent/GB9913458D0/en active Pending
-
2000
- 2000-06-08 WO PCT/GB2000/002234 patent/WO2000074680A1/en not_active Ceased
- 2000-06-08 AU AU55432/00A patent/AU766748B2/en not_active Ceased
- 2000-06-08 CA CA002376215A patent/CA2376215A1/en not_active Abandoned
- 2000-06-08 JP JP2001501216A patent/JP2003501387A/ja active Pending
- 2000-06-08 AT AT00940504T patent/ATE302006T1/de not_active IP Right Cessation
- 2000-06-08 DE DE60022033T patent/DE60022033T2/de not_active Expired - Fee Related
- 2000-06-08 EP EP00940504A patent/EP1185268B1/en not_active Expired - Lifetime
- 2000-06-08 ES ES00940504T patent/ES2243273T3/es not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115631B2 (en) | 1995-12-04 | 2006-10-03 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| US7431944B2 (en) | 1995-12-04 | 2008-10-07 | Celgene Corporation | Delivery of multiple doses of medications |
| US7459560B2 (en) | 1997-05-22 | 2008-12-02 | Celgene Corporation | Processes and intermediates for resolving piperidyl acetamide stereoisomers |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2243273T3 (es) | 2005-12-01 |
| WO2000074680A1 (en) | 2000-12-14 |
| EP1185268A1 (en) | 2002-03-13 |
| AU766748B2 (en) | 2003-10-23 |
| ATE302006T1 (de) | 2005-09-15 |
| DE60022033D1 (de) | 2005-09-22 |
| AU5543200A (en) | 2000-12-28 |
| DE60022033T2 (de) | 2006-03-30 |
| EP1185268B1 (en) | 2005-08-17 |
| GB9913458D0 (en) | 1999-08-11 |
| JP2003501387A (ja) | 2003-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| van Lemmen et al. | Opioid overdose: limitations in naloxone reversal of respiratory depression and prevention of cardiac arrest | |
| Gatley et al. | Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans | |
| JP5203373B2 (ja) | 痛みの治療のための混合されたＯＲＬ１／μ−アゴニスト | |
| Overton | Comparison of the degree of discriminability of various drugs using the T-maze drug discrimination paradigm | |
| Glowa et al. | Effects of dopamine reuptake inhibitors on food-and cocaine-maintained responding: II. Comparisons with other drugs and repeated administrations. | |
| de La Garza et al. | The discriminative stimulus properties of cocaine in the rhesus monkey | |
| Doggrell et al. | Treatment of dementia with neurotransmission modulation | |
| CN102307895A (zh) | 用于治疗或预防麻醉药停药症状的方法和组合物 | |
| Wiley et al. | Nicotine-like discriminative stimulus effects of bupropion in rats. | |
| EP1185268B1 (en) | The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder | |
| Tanda et al. | Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change | |
| Witkin et al. | Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine | |
| Steinpreis et al. | Methadone produces conditioned place preference in the rat | |
| Snyder | Revisiting old friends: update on opioid pharmacology | |
| Li et al. | Place conditioning and locomotor effects of N-substituted, 4′, 4′′-difluorobenztropine analogs in rats | |
| Platt et al. | Discriminative stimulus effects of intravenous heroin and its metabolites in rhesus monkeys: opioid and dopaminergic mechanisms | |
| WO2021174116A1 (en) | Methods for opiate and opioid overdose prevention and reversal | |
| Platt et al. | Opioid receptors and the discriminative stimulus effects of ethanol in squirrel monkeys: Mu and delta opioid receptor mechanisms | |
| Kozikowski et al. | Mixed cocaine agonist/antagonist properties of (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate, a piperidine-based analog of cocaine | |
| Snyder et al. | Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders | |
| Moscovici et al. | Epidural scopolamine administration in preventing nausea after epidural morphine | |
| Zapata et al. | Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan | |
| Aurilio et al. | Treatment of ischemic pain in patients suffering from peripheral vasculopathy with transdermal buprenorphine plus epidural morphine with ropivacaine vs. epidural morphine with ropivacaine | |
| Witkin et al. | Toxicity: Mechanisms and Pharmacotherapy | |
| WO2021025985A1 (en) | Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |